Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Our 22 production lines for finished formulations across four facilities are complimented by three facilities for Active Pharmaceutical Ingredients (API). Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth.
The ability to provide therapeutic medicines on the best quality parameters and at the right price, is the overriding objective for us at Gland Pharma. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. Over the years, we have been able to move ahead on both those counts, to establish a presence across the entire value chain in Injectables.
A manufacturing base with installed capacity of 750 million units per annum spread over seven facilities; proven Research and Development wing; pan-India and global distribution and sales network; affiliation with national and state level healthcare institutions; compliance with all necessary regulatory boards; and a high level of approvals and pending filings in our area of operations, all contribute to our standing in the pharma domain.
Our family of investors and other stakeholders are the driving force that gives us a sharp focus on good governance in all our areas of operations and services. And by doing so, we are reiterating our firm resolve to deliver value and satisfaction.
With an MBBS from Osmania University, India and Science of Medicine from East Carolina, University School of Medicine, USA, where he continued in hospital-based practice for seven years, Dr. Penmetsa joined Gland Pharma as Executive Director, in 1992. Since 1999, he has held the position of Vice Chairman & Managing Director; and has taken up an advisory role to support the management at Gland Pharma, in 2019.
Member of the International Leadership Forum (ILF) and the International Society for Pharmaceutical Engineering (ISPE); Dr. Penmetsa is also one of Fosun’s Global partners and the Chief Representative in India.
Mr. Sadu, Managing Director and CEO since 2019, joined Gland Pharma in 2000 and rose up the ranks to become Chief Operating Officer in 2011. Beginning his career in Marketing at Smith Kline Beecham USA, he holds MS qualifications in Industrial Pharmacy from Long Island University, New York; MBA from University of Maryland, Baltimore; and postgraduate certification in Finance and Management from London School of Business and Finance. He has over 20 years of varied experience in International Business Development, Alliancing, Production, Engineering, Product Development and Supply Chain Management
Mr Raju’s association with the company goes back since its inception and he has closely been connected in putting into place quality control norms and practices as envisaged by our founder. With over 38 years’ experience in Quality Assurance, Quality Control and Regulatory Affairs, Mr Raju holds a Master of Science in Organic Chemistry and Post Graduate Diploma in Industrial Microbiology.
Mr Mitra joined Gland Pharma as CFO in 2019. He is a Qualified Chartered Accountant and Company Secretary with Associate Membership of the respective institutes.
He has over 20 years’ experience in leading Financial Management, FP&A, Strategic Planning, Investor Relations in Pharmaceutical and other industries.